G6PD and hydrops fetalis: Figure S1b, left) and cardiac fibroblasts (136.9±4.3% vs. control. Figure S1b, right). Moreover, HF increased caspase-3 expression and the release of glucose 6-phosphate dehydrogenase (G6PD), a marker of necrosis (Figure S1c). Interestingly, GLP-1 pre-treatment mitigated HF-/HG-induced hypertrophy (97.2±7.5% and 94.3±6.9% vs. HF and HG, respectively) and HF-induced cardiomyocyte and cardiac fibroblast death (123.6±8.3% and 115.2±6.3% vs. control), and decreased the related pro-hypertrophic and apoptotic/necrotic markers (Figure S1a, c).